PTEN in kidney cancer: A review and meta-analysis

Kidney cancer is one of the most common cancers in the USA causing 14,400 deaths per year. The phosphatase and tensin homolog (PTEN) has been extensively documented as a tumor suppresser gene in cancer. However, there is unclear evidence for its clinicopathological and prognostic role in kidney canc...

Full description

Saved in:
Bibliographic Details
Published in:Clinica chimica acta 2018-05, Vol.480, p.92-98
Main Authors: Que, Wan-cai, Qiu, Hong-qiang, Cheng, Yu, Liu, Mao-bai, Wu, Chao-yang
Format: Article
Language:English
Subjects:
Clinicopathological feature
Kidney cancer
Meta-analysis
Phosphatase and tensin homolog
Prognosis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Kidney cancer is one of the most common cancers in the USA causing 14,400 deaths per year. The phosphatase and tensin homolog (PTEN) has been extensively documented as a tumor suppresser gene in cancer. However, there is unclear evidence for its clinicopathological and prognostic role in kidney cancer. A systematic review of literature assessing PTEN expression and clinical outcome in patients with kidney cancer. Web of Science, PubMed, Embase, and Chinese databases were searched for collecting for the eligible studies providing sufficient information. Pooled odds ratios (ORs) and hazard ratios (HRs) were respectively used to evaluate the association between PTEN levels and the clinicopathological features and clinical outcomes. A total of 35 studies enrolling 4532 patients were finally included in this study. For the survival outcome, the result suggested that shorter overall survival (OS) was correlated with low PTEN expression (HR = 0.57, 95% CIs: 0.45–0.74, P 
ISSN:0009-8981
1873-3492
DOI:10.1016/j.cca.2018.01.031